Business Context and Reporting Period
This Form 8-K is a current report filed by NantKwest, Inc. (not Immunitybio, Inc.) on February 5, 2021. The filing discloses compensatory arrangements for Richard Adcock, the Company's Chief Executive Officer, effective from his appointment on October 26, 2020.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity figures. The document focuses exclusively on equity compensation details.
- Option Grant: 750,000 options to purchase common stock.
- Exercise Price: $23.72 per share (closing price on Nasdaq on the grant date).
- RSU Awards: Total of 400,000 Restricted Stock Units.
- Immediate Vesting: 150,000 shares (subject to tax withholding).
- Time-Based Vesting: 250,000 shares vesting over three years.
Material Changes
The filing reports a modification to the equity grant originally recommended in Mr. Adcock's Offer of Employment. The Compensation Committee granted the awards on February 5, 2021, to align with his role as CEO.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of general business risks. The primary contingency noted is that all time-based vesting is subject to Mr. Adcock remaining in "Continuous Service" through the applicable vesting dates.
Investor Verification Checklist
- Verify the total dilution impact of the 1,150,000 total equity units (options and RSUs) granted to the CEO.
- Confirm the vesting schedule details: 1/3 of options and 1/3 of the deferred RSUs vest annually for three years.
- Review the Company's Amended and Restated 2015 Equity Incentive Plan for remaining share availability.
- Note that the filing explicitly identifies the registrant as NantKwest, Inc., not Immunitybio, Inc.